Use of oritavancin for prevention and treatment of anthrax
US9089507B2 · kind B2 · utility
0Cited by
0References
16Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 24, 2007 |
| Grant date | Jul 28, 2015 |
| Priority date | — |
| Expiry date | Jun 21, 2029 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P31/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Glycopeptide antibiotics, such as oritavancin, demonstrate significant activity against B. anthracis. Methods for the treatment, prophylaxis and prevention of B. anthracis infection and disease in animals, including humans, are described.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.